Submit Your Feeds

Business News • PR NewsWire • Neuralstem and Summit Pharmaceuticals Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan

Neuralstem and Summit Pharmaceuticals Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan
Neuralstem and Summit Pharmaceuticals Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan

ROCKVILLE, Md., June 7, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.  Under the a

View More : http://www.prnewswire.com/news-releases/neuralstem-and-summit-pharmaceuticals-enter-into-exclusive-agency-agreement-to-l...
Releted News by prnewswire
International Drug & Explosives Detection Company IDenta Corp. Announces Agreements With New Distributors
Neuralstem and Summit Pharmaceuticals Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan
New iPhone App, Website and Facebook Walking Game—Arookoo—Steps Up Social Gaming
Home Sitemap Contact Us
© businessNewsNewsNews.com